Business
NetworkNewsWire Announces Publication Highlighting Advances in CBD Development
New York, New York--(Newsfile Corp. - October 30, 2017) - NetworkNewsWire ("NNW"), a multifa...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication Highlighting Advances in CBD DevelopmentNew York, New York--(Newsfile Corp. - October 30, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.The publication, titled, \"Biotechs Develop Proprietary Systems to Drive CBD Research and Development,\" discusses varying processes to produce high-purity cannabinoids for medicinal purposes. To view the full publication, visit: https://www.networknewswire.com/biotechs-develop-proprietary-systems-drive-cbd-research-development/ \"InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) is the standout company in the field of pharmaceutical-grade cannabinoid biosynthesis. By using its proprietary systems and methods, InMed has developed the first bio-identical cannabinoid that has undergone formulation and preclinical testing. InMed will use its proprietary systems to develop other cannabinoid-based drugs, leveraging its technology to ensure enhanced consistency in production, purity, quality and structural integrity, all of which greatly increase the likelihood of gaining FDA approval for its candidates.\"InMed's biosynthesis platform has several other advantages over agriculture-based production methods, including extensive cost savings resulting from not having to contend with the grow-harvest-extract-purify cycle necessary when using cannabis crops. Additionally, InMed's biosynthesis process can produce all of the 90+ cannabinoids naturally found in cannabis, enabling the company to avoid the harmful chemicals that are used in the cannabis growing process and offering an easier way to scale-up from the laboratory to full production.\"The company has streamlined its proprietary systems, enabling it to create bio-identical cannabinoids in the controlled setting of a laboratory, and it is currently working on scaling up its manufacturing capability. Once at commercial scale, the company will be uniquely positioned to maximize its potential by assisting other companies with cannabinoid-based drug development programs.\" About InMed InMed is a preclinical stage biopharmaceutical comp...